GB2618753A - Compositions and methods for improving relaxation, sleep, cognition, and/or physical performance - Google Patents
Compositions and methods for improving relaxation, sleep, cognition, and/or physical performance Download PDFInfo
- Publication number
- GB2618753A GB2618753A GB2313513.0A GB202313513A GB2618753A GB 2618753 A GB2618753 A GB 2618753A GB 202313513 A GB202313513 A GB 202313513A GB 2618753 A GB2618753 A GB 2618753A
- Authority
- GB
- United Kingdom
- Prior art keywords
- butanediol
- synergistic
- composition according
- theanine
- caffeine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract 80
- 238000000034 method Methods 0.000 title claims abstract 16
- 230000036314 physical performance Effects 0.000 title claims abstract 6
- 230000019771 cognition Effects 0.000 title abstract 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims abstract 90
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract 66
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract 63
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract 33
- 229960001948 caffeine Drugs 0.000 claims abstract 33
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract 33
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 claims abstract 30
- PUPZLCDOIYMWBV-SCSAIBSYSA-N (R)-butane-1,3-diol Chemical compound C[C@@H](O)CCO PUPZLCDOIYMWBV-SCSAIBSYSA-N 0.000 claims abstract 17
- PUPZLCDOIYMWBV-BYPYZUCNSA-N (S)-butane-1,3-diol Chemical compound C[C@H](O)CCO PUPZLCDOIYMWBV-BYPYZUCNSA-N 0.000 claims abstract 6
- 230000002195 synergetic effect Effects 0.000 claims 63
- 235000019437 butane-1,3-diol Nutrition 0.000 claims 33
- 235000013361 beverage Nutrition 0.000 claims 8
- 230000003931 cognitive performance Effects 0.000 claims 4
- 239000011885 synergistic combination Substances 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000024335 physical disease Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention comprises compositions and methods for improving relaxation, sleep, cognition, and/or physical performance. Compositions may include therapeutically effective amounts of 1,3-butanediol, in the form of R-1,3-butanediol, S-1,3-butanediol, or racemic 1,3-butanediol, in combination with a therapeutically effective amount of one or more additional active ingredients selected from caffeine, L-theanine, and a mixture of caffeine and L-theanine. Compositions may further include synergistically effective amounts of 1,3-butanediol, in the form of R-1,3-butanediol, S-1,3-butanediol, or racemic 1,3-butanediol, in combination with a synergistically effective amount of caffeine, L-theanine, or a mixture of caffeine and L-theanine.
Claims (1)
1. A composition comprising: 1.3 -butanediol selected from R- 1,3 -butanediol, S-l,3-butanediol, and racemic 1,3- butanediol in an amount from 1 mg to 100 g; and caffeine in an amount from 10 mg to 1 g.
2. The composition according to claim 1, comprising from 5 g to 35 g 1,3 -butanediol and from 50 mg to 300 mg caffeine.
3. The composition according to claims 1 or 2, comprising a ratio (w/w) of caffeine to 1,3- butanediol within a range from 1:50 to 1:350.
4. The composition according to any one of claims 1 to 3, further comprising L-theanine in an amount from 10 mg to 1 g.
5. The composition according to any one of claims 1 to 4, comprising from 100 mg to 300 mg L-theanine.
6. The composition according to claims 4 or 5, comprising a ratio (w/w) of caffeine to L- theanine within a range from 1:2 to 2:1.
7. The composition according to any one of claims 1 to 6, wherein the 1,3 -butanediol is R- 1.3-butanediol.
8. The composition according to any one of claims 1 to 7, wherein said composition is prepared in a beverage form.
9. A method of improving cognitive and/or physical performance in a subject, comprising: administering to the subject the composition according to any one of claims 1 to 8.
10. The method according to claim 9, wherein the composition comprises about 10 g R-1,3- butanediol and about 200 mg caffeine and the composition is administered about 30 minutes before a cognitively and/or physically demanding task, not more than three times per day.
11. A composition comprising: 1.3 -butanediol selected from R- 1,3 -butanediol, S-l,3-butanediol, and racemic 1,3- butanediol in an amount from 1 mg to 100 g; and L-theanine in an amount from 10 mg to 1 g.
12. The composition according to claim 11, comprising from 10 g to 35 g 1,3 -butanediol and from 50 mg to 400 mg L-theanine. The composition according to claims 11 or 12, comprising a ratio (w/w) of L-theanine to 1.3 -butanediol within a range from 1:50 to 1:700. The composition according to any one of claims 11 to 13, wherein the 1,3-butanediol is R- 1.3-butanediol. The composition according to any of claims 11 to 14, wherein said composition is prepared in a beverage form. The composition according to any one of claims 11 to 15, further comprising caffeine in an amount from 10 mg to 1 g. The composition according to any one of claims 11 to 16, comprising from 100 mg to 300 mg caffeine. The composition according to claims 16 or 17, comprising a ratio (w/w) of caffeine to L- theanine within a range from 1:2 to 2:1. A method of improving cognitive and/or physical performance in a subject, comprising: administering to the subject the composition according to any one of claims 11 to
18. A method of improving relaxation or sleep performance in a subject, comprising: administering to the subject the composition according to any one of claims 11 to 15. A synergistic composition comprising synergistically effective amounts of 1,3-butanediol, selected from R- 1,3-butanediol, S- 1,3-butanediol, and racemic 1,3-butanediol, and caffeine. The synergistic composition according to claim 21, comprising a ratio (w/w) of caffeine to 1.3-butanediol within a range from 1:50 to 1:700. The synergistic composition according to claims 21 or 22, comprising from 1 mg to 100 g 1,3-butanediol and from 10 mg to 1 g caffeine. The synergistic composition according to any one of claims 21 to 23, comprising from 10 g to 35 g 1,3-butanediol and from 100 mg to 300 mg caffeine. The synergistic composition according to any one of claims 21 to 24, wherein the 1,3- butanediol is R- 1,3 -butanediol. The synergistic composition according to any one of claims 21 to 25, further comprising a synergistically effective amount of L-theanine. The synergistic composition of claim 26, comprising from 50 mg to 400 mg L-theanine. The synergistic composition according to claims 26 or 27, comprising a ratio (w/w) of caffeine to L-theanine within a range from 1:2 to 2:1. The synergistic composition according to any one of claims 21 to 28, wherein said synergistic composition is prepared in a beverage form. A method of improving cognitive and/or physical performance in a subject, the method comprising the step of administering to the subject the synergistic composition according to any of claims 21 to
29. A synergistic composition for the treatment of a cognitive or physical disorder in a subject, wherein said synergistic composition comprises synergistically effective amounts of 1,3- butanediol, selected from R- 1,3 -butanediol, S- 1,3 -butanediol, and racemic 1,3 -butanediol, and caffeine. The synergistic composition according to claim 31, comprising a ratio (w/w) of 1,3- butanediol : caffeine within a range from 50:1 to 700:1. The synergistic composition according to claims 31 or 32, comprising from 1 mg to 100 g 1.3 -butanediol and from 10 mg to 1 g caffeine. The synergistic composition according to any one of claims 31 to 33, comprising from 10 g to 35 g 1,3 -butanediol and from 100 mg to 300 mg caffeine. The synergistic composition according to any one of claims 31 to 34, wherein the 1,3- butanediol is R- 1,3 -butanediol. The synergistic composition according to any one of claims 31 to 35, further comprising a synergistically effective amount of L-theanine. The synergistic composition of claim 36, comprising from 50 mg to 400 mg L-theanine. The synergistic composition according to claims 36 or 37, comprising a ratio (w/w) of caffeine to L-theanine within a range from 1:2 to 2:1. The synergistic composition according to any of claims 31 to 38, wherein said synergistic composition is prepared in a beverage form. A synergistic product comprising a synergistic amount of 1,3 -butanediol, selected from R- 1.3 -butanediol, S-l,3-butanediol, and racemic 1,3-butanediol, and caffeine as a combined preparation for simultaneous use in the treatment of a cognitive and/or physical disorder in a subject. The synergistic product according to claim 40, wherein the synergistic amount comprises a ratio (w/w) of 1,3 -butanediol : caffeine within a range from 50:1 to 700:1. The synergistic product according to claims 40 or 41, wherein the synergistic amount comprises from 1 mg to 100 g 1,3 -butanediol and from 10 mg to 1 g caffeine. The synergistic product according to any one of claims 40 to 42, wherein the synergistic amount comprises from 10 g to 35 g 1,3 -butanediol and from 100 mg to 300 mg caffeine. The synergistic product according to any one of claims 40 to 43, wherein the 1,3 -butanediol is R-l,3-butanediol. The synergistic product according to any one of claims 40 to 44, further comprising a synergistically effective amount of L-theanine. The synergistic product of claim 45, wherein the synergistic amount of L-theanine comprises from 50 mg to 400 mg L-theanine. The synergistic product according to claims 45 or 46, wherein the synergistic amounts of L-theanine and caffeine comprise a ratio (w/w) of caffeine to L-theanine within a range from 1:2 to 2:1. The synergistic product according to any of claims 40 to 47, wherein said synergistic product is prepared in a beverage form. A synergistic composition comprising a synergistic combination of compounds present in synergistically effective amounts, wherein the synergistic combination is a combination consisting essentially of 1,3-butanediol, selected from R-l,3-butanediol, S-l,3-butanediol, and racemic 1,3-butanediol, and caffeine. The synergistic composition according to claim 49, comprising a ratio (w/w) of 1,3- butanediol : caffeine within a range from 50:1 to 700:1. The synergistic composition according to claims 49 or 50, comprising from 1 mg to 100 g 1,3-butanediol and from 10 mg to 1 g caffeine. The synergistic composition according to any one of claims 49 to 51, comprising from 10 g to 35 g 1,3-butanediol and from 100 mg to 300 mg caffeine. The synergistic composition according to any one of claims 49 to 52, wherein the 1,3- butanediol is R- 1,3 -butanediol. The synergistic composition according to any one of claims 49 to 53, further consisting essentially of a synergistically effective amount of L-theanine. The synergistic composition of claim 54, comprising from 50 mg to 400 mg L-theanine. The synergistic composition according to claims 54 or 55, comprising a ratio (w/w) of caffeine to L-theanine within a range from 1:2 to 2:1. The synergistic composition according to any one of claims 49 to 56, wherein said synergistic composition is prepared in a beverage form. A method of improving cognitive and/or physical performance in a subject, the method comprising the step of administering to the subject the synergistic composition according to any of claims 49 to
57. A synergistic composition comprising synergistically effective amounts of 1,3-butanediol, selected from R- 1,3-butanediol, S- 1,3-butanediol, and racemic 1,3-butanediol, and L- theanine. The synergistic composition according to claim 59, comprising a ratio (w/w) of L-theanine to 1,3-butanediol within a range from 1:50 to 1:700. The synergistic composition according to claims 59 or 60, comprising from 1 mg to 100 g 1,3-butanediol and from 10 mg to 1 g L-theanine. The synergistic composition according to any of claims 59 to 61, comprising from 10 g to 35 g 1,3-butanediol and from 50 mg to 400 mg L-theanine. The synergistic composition according to any one of claims 59 to 62, wherein the 1,3- butanediol is R- 1,3 -butanediol. The synergistic composition according to any one of claims 59 to 63, wherein said synergistic composition is prepared in a beverage form. A method of improving relaxation or sleep performance in a subject, the method comprising the steps of administering to the subject the composition according to any of claims 59 to 64. The method according to claim 65, wherein the composition is administered about 30 minutes before desired relaxation or sleep. A synergistic composition comprising a synergistic combination of compounds present in synergistically effective amounts, wherein the synergistic combination is a combination consisting essentially of 1,3-butanediol, selected from R- 1,3-butanediol, S- 1,3-butanediol, and racemic 1,3-butanediol, and L-theanine. The synergistic composition according to claim 67, comprising a ratio (w/w) of L-theanine to 1,3 -butanediol within a range from 1:50 to 1:700. The synergistic composition according to claims 67 or 68, comprising from 1 mg to 100 g 1,3 -butanediol and from 10 mg to 1 g L-theanine. The synergistic composition according to any of claims 67 to 69, comprising from 10 g to 35 g 1,3 -butanediol and from 50 mg to 400 mg L-theanine. The synergistic composition according to any one of claims 67 to 70, wherein the 1,3- butanediol is R- 1,3 -butanediol. The synergistic composition according to any one of claims 67 to 71, wherein said synergistic composition is prepared in a beverage form. A method of improving relaxation or sleep performance in a subject, the method comprising the steps of administering to the subject the composition according to any of claims 67 to 72. The method according to claim 73, wherein the composition is administered about 30 minutes before desired relaxation or sleep.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163146413P | 2021-02-05 | 2021-02-05 | |
| US17/570,925 US20220249497A1 (en) | 2021-02-05 | 2022-01-07 | Compositions and methods for improving relaxation, sleep, cognition, and/or physical performance |
| PCT/US2022/014916 WO2022169852A1 (en) | 2021-02-05 | 2022-02-02 | Compositions and methods for improving relaxation, sleep, cognition, and/or physical performance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202313513D0 GB202313513D0 (en) | 2023-10-18 |
| GB2618753A true GB2618753A (en) | 2023-11-15 |
Family
ID=82703436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2313513.0A Pending GB2618753A (en) | 2021-02-05 | 2022-02-02 | Compositions and methods for improving relaxation, sleep, cognition, and/or physical performance |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20220249497A1 (en) |
| EP (1) | EP4288039A1 (en) |
| GB (1) | GB2618753A (en) |
| WO (1) | WO2022169852A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015199142A1 (en) * | 2014-06-25 | 2015-12-30 | 花王株式会社 | Packageable beverage |
| WO2020041871A1 (en) * | 2018-08-27 | 2020-03-05 | Exerkine Corporation | Method for treating lysosomal storage disease |
| US20200077690A1 (en) * | 2018-09-06 | 2020-03-12 | Ross Steinberg | Exogenous Ketone Composition |
| WO2020167690A1 (en) * | 2019-02-11 | 2020-08-20 | Access Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| US20200397792A1 (en) * | 2019-06-21 | 2020-12-24 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190313682A1 (en) * | 2018-04-12 | 2019-10-17 | Metabolic Recovery Systems, LLC | Compositions and methods for supplementing the diet |
| WO2021178547A1 (en) * | 2020-03-05 | 2021-09-10 | Devon Price | COMPOSITION OF (D)-β-HYDROXYBUTYRIC ACID, (D)-β-HYDROXYVALERIC ACID, AND (D)-1,3 BUTANEDIOL AS A NUTRITIONAL SUPPLEMENT AND THERAPEUTIC AGENT |
-
2022
- 2022-01-07 US US17/570,925 patent/US20220249497A1/en not_active Abandoned
- 2022-02-02 US US18/273,510 patent/US20240041891A1/en active Pending
- 2022-02-02 EP EP22750312.5A patent/EP4288039A1/en active Pending
- 2022-02-02 WO PCT/US2022/014916 patent/WO2022169852A1/en active Application Filing
- 2022-02-02 GB GB2313513.0A patent/GB2618753A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015199142A1 (en) * | 2014-06-25 | 2015-12-30 | 花王株式会社 | Packageable beverage |
| WO2020041871A1 (en) * | 2018-08-27 | 2020-03-05 | Exerkine Corporation | Method for treating lysosomal storage disease |
| US20200077690A1 (en) * | 2018-09-06 | 2020-03-12 | Ross Steinberg | Exogenous Ketone Composition |
| WO2020167690A1 (en) * | 2019-02-11 | 2020-08-20 | Access Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| US20200397792A1 (en) * | 2019-06-21 | 2020-12-24 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240041891A1 (en) | 2024-02-08 |
| US20220249497A1 (en) | 2022-08-11 |
| WO2022169852A1 (en) | 2022-08-11 |
| EP4288039A1 (en) | 2023-12-13 |
| GB202313513D0 (en) | 2023-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5148271B2 (en) | Formulations containing capsaicinoids, local anesthetics and / or antipruritics for pain treatment | |
| US11793794B2 (en) | Combination therapy for treating or preventing depression or other mood diseases | |
| JP6112867B2 (en) | Treatment of loss of touch with saxitoxin derivatives | |
| EP0748220A1 (en) | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex | |
| JPH06508836A (en) | Methods and compositions for the treatment of emesis, nausea and other disorders using optically pure R(+) ondansetron | |
| AP1849A (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| CA2459470A1 (en) | Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use | |
| WO2004096118B1 (en) | Composition for improving cognition and memory | |
| MX2023007080A (en) | Method for treating fibrosis. | |
| MX2009002311A (en) | Pharmaceutical compositions for the treatment of fungal infections. | |
| GB2618753A (en) | Compositions and methods for improving relaxation, sleep, cognition, and/or physical performance | |
| US4435424A (en) | Process for improving vigor and mood in normal human patients | |
| MX2021016055A (en) | Isoxazoline parasiticide formulations and methods for treating blepharitis. | |
| CN113646045A (en) | Therapeutic agent for dyskinesia | |
| WO2008035177A2 (en) | Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor | |
| JPH01153665A (en) | Use of dihydrophenylamino acid derivative for immune modulation and cell breeding suppression and pharmacological composition containing the same | |
| AU2021311245A8 (en) | Compound for androgen receptor degradation, and pharmaceutical use thereof | |
| Presthus | BC 105 AND METHYSERGIDE (DESERIL®) IN MIGRAINE PROPHYLAXIS | |
| GB2619486A (en) | Compositions and methods for improving brain function | |
| KR102543754B1 (en) | Injection composition for lipolysis | |
| Bhargava et al. | Diclofenac patch: a better alternative to injectable diclofenac in postoperative pain management | |
| US20230405077A1 (en) | Composition for treating pain and method of use thereof | |
| WO2023154450A3 (en) | (ampa-pam)-nmda receptor antagonist combination therapy for treatment of mental conditions and disorders | |
| JP7156825B2 (en) | External pharmaceutical composition | |
| JPH061721A (en) | Pain treating agent and pain mitigating activity potentiator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40104127 Country of ref document: HK |